JP7827737B2 - Ｖｅｇｆａ結合分子 - Google Patents

Ｖｅｇｆａ結合分子

Info

Publication number
JP7827737B2
JP7827737B2 JP2023550552A JP2023550552A JP7827737B2 JP 7827737 B2 JP7827737 B2 JP 7827737B2 JP 2023550552 A JP2023550552 A JP 2023550552A JP 2023550552 A JP2023550552 A JP 2023550552A JP 7827737 B2 JP7827737 B2 JP 7827737B2
Authority
JP
Japan
Prior art keywords
antigen
vegfa
fold
cancer
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023550552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512260A (ja
JP2024512260A5 (enExample
Inventor
アシアル，イグナシオ
Original Assignee
ドットバイオ プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドットバイオ プライベート リミテッド filed Critical ドットバイオ プライベート リミテッド
Publication of JP2024512260A publication Critical patent/JP2024512260A/ja
Publication of JP2024512260A5 publication Critical patent/JP2024512260A5/ja
Application granted granted Critical
Publication of JP7827737B2 publication Critical patent/JP7827737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023550552A 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子 Active JP7827737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202101681W 2021-02-19
SG10202101681W 2021-02-19
PCT/EP2022/054123 WO2022175474A1 (en) 2021-02-19 2022-02-18 Vegfa-binding molecules

Publications (3)

Publication Number Publication Date
JP2024512260A JP2024512260A (ja) 2024-03-19
JP2024512260A5 JP2024512260A5 (enExample) 2024-11-14
JP7827737B2 true JP7827737B2 (ja) 2026-03-10

Family

ID=80685523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023550552A Active JP7827737B2 (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子
JP2023550275A Pending JP2024513644A (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023550275A Pending JP2024513644A (ja) 2021-02-19 2022-02-18 Ｖｅｇｆａ結合分子

Country Status (9)

Country Link
US (2) US20240228602A9 (enExample)
EP (2) EP4294839A1 (enExample)
JP (2) JP7827737B2 (enExample)
KR (2) KR20230165902A (enExample)
CN (2) CN117279941A (enExample)
AR (1) AR124917A1 (enExample)
AU (2) AU2022223337A1 (enExample)
CA (2) CA3208389A1 (enExample)
WO (2) WO2022175474A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024055995A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa融合蛋白及其制备方法和应用
JP2025534252A (ja) * 2022-09-14 2025-10-15 尋済生物科技（北京）有限公司 抗ｖｅｇｆａ抗体またはその抗原結合フラグメント、およびその使用
CN119039450A (zh) * 2023-05-22 2024-11-29 上海君实生物医药科技股份有限公司 抗pd-1-抗vegf的双特异性抗体、其药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541939A (ja) 2010-09-03 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｖｅｇｆ結合分子
JP2014523746A (ja) 2011-07-27 2014-09-18 グラクソ グループ リミテッド Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
KR100883430B1 (ko) * 2007-06-13 2009-02-12 한국생명공학연구원 혈관내피성장인자 수용체를 중화하는 인간 단클론항체 및그 용도
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP6921743B2 (ja) * 2014-11-05 2021-08-18 ナンヤン テクノロジカル ユニヴァーシティー 安定化かつ自律性抗体ｖｈドメイン
AU2015376558B9 (en) * 2015-01-06 2021-07-01 Zhuhai Essex Bio-Pharmaceutical Co., Ltd. Anti-VEGF antibody
EP3565898A4 (en) * 2017-01-05 2021-05-26 Helix Biopharma Corp. VEGFR-2-CAR IMMUNE CELLS FOR TREATMENT OF CANCER
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541939A (ja) 2010-09-03 2013-11-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｖｅｇｆ結合分子
JP2014523746A (ja) 2011-07-27 2014-09-18 グラクソ グループ リミテッド Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fatemeh Kazemi-Lomedasht et al.，Molecular Immunology，2015年，Vol. 65，pp. 58-67
Walead Ebrahimizadeh et al.，Appl Biochem Biotechnol，2015年，Vol. 176，pp. 1985-1995
Zahra Farajpour et al.，Biochemical and Biophysical Research Communications，2014年，Vol. 446，pp. 132-136

Also Published As

Publication number Publication date
EP4294838A1 (en) 2023-12-27
US20240228602A9 (en) 2024-07-11
CN117242092A (zh) 2023-12-15
EP4294839A1 (en) 2023-12-27
AR124917A1 (es) 2023-05-17
CN117279941A (zh) 2023-12-22
US20240228601A9 (en) 2024-07-11
CA3208368A1 (en) 2022-08-25
KR20230165902A (ko) 2023-12-05
AU2022222311A1 (en) 2023-09-21
KR20230165901A (ko) 2023-12-05
AU2022223337A1 (en) 2023-09-21
CA3208389A1 (en) 2022-08-25
JP2024512260A (ja) 2024-03-19
US20240132579A1 (en) 2024-04-25
US20240132580A1 (en) 2024-04-25
JP2024513644A (ja) 2024-03-27
WO2022175474A1 (en) 2022-08-25
WO2022175481A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
TWI883044B (zh) 使用her3抗原結合分子的癌症之治療及預防
JP7825000B2 (ja) Ｈｅｒ３抗原結合性分子
JP6449441B2 (ja) ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物
US20240132580A1 (en) Vegfa-binding molecules
CN114437227A (zh) 双特异抗体及其应用
US20260132219A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40073393A (en) Bispecific antibody and use thereof
HK40026637A (en) Her3 antigen-binding molecules
HK40026637B (en) Her3 antigen-binding molecules

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240319

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260226

R150 Certificate of patent or registration of utility model

Ref document number: 7827737

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150